This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Dulaglutide
GLP-1 Receptor Agonist (Long-acting)
/WHAT_IT_IS
Dulaglutide is a long-acting GLP-1 receptor agonist composed of two GLP-1 analog chains fused to an IgG4 Fc fragment. In research settings it’s used to study glucose homeostasis, gastric emptying, appetite regulation, and cardiometabolic outcomes.
/USAGE
Investigated for improving glycemic control, reducing cardiometabolic risk markers, and modeling weight/appetite pathways via incretin signaling.
/MECHANISM_OF_ACTION
Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and reduce appetite through central and peripheral pathways.
Reported Benefits
- +Improved fasting and postprandial glucose
- +Reduced A1c in type 2 diabetes models
- +Decreased appetite and body weight in study populations
- +Potential cardiovascular risk-marker improvements
Reported Side Effects
- −Nausea, vomiting, diarrhea, or constipation
- −Abdominal pain or decreased appetite
- −Injection-site reactions
- −Rare: pancreatitis, gallbladder disease
- −Hypoglycemia when combined with insulin or sulfonylureas
- −Boxed warning (rodent): thyroid C-cell tumors; contraindicated with personal/family history of MTC or MEN2 in clinical use contexts
/STACKED_WITH
/RESEARCH_NOTES
Human prescription biologic; use in controlled research settings with appropriate monitoring (glucose, A1c, renal/hepatic function, triglycerides). Assess GI tolerance and pancreatitis/gallbladder risk factors in study designs.
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.